SecBot SecBot
8-K ·Filed Jun 11, 2026

OCGN

Ocugen, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001104659-26-073015
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor next 10-Q for pipeline updates and cash runway; no immediate trading catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.21
T+0 close · Jun 11, 2026 · via day close
Latest settled
+9.92%
T+60 · $1.33
Vs SPY
+6.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $1.21entry
  2. T+1 · 5mo ago +0.83%α −0.94% · $1.22
  3. T+5 · 5mo ago +2.48%α +1.81% · $1.24
  4. T+20 · 4mo ago +21.49%α +19.71% · $1.47
  5. T+60 · 2mo ago +9.92%α +6.65% · $1.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointment of Mohamed Genead, M.D., M.Sc., as Chief Medical Officer. All four stockholder proposals passed, including election of two Class III directors, ratification of PwC as auditor, and advisory approval of executive compensation on an annual frequency. The CMO appointment formalizes a role held on an interim basis since May 8, 2026, no material business or financial implications.

Key Facts

  • Total of 139,628,075 shares of common stock represented at the Annual Meeting.
  • Kirsten Castillo, MBA, and Satish Chandran, Ph.D. were elected as Class III directors until 2029.
  • PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026 with 136,784,245 votes for.
  • Advisory say-on-pay approved with 49,968,948 for vs. 13,245,090 against (excluding broker non-votes).
  • Stockholders selected a one-year frequency for future advisory votes on executive compensation.
  • Mohamed Genead, M.D., M.Sc., appointed Chief Medical Officer effective June 11, 2026 (previously Acting/Interim CMO since May 8, 2026).

Financial Impact

No financial impact; administrative and governance actions only.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-073015
Document: 0001104659-26-073015-index-headers.html0001104659-26-073015
Document: 0001104659-26-073015-index.html0001104659-26-073015
Document: 0001104659-26-073015.txt0001104659-26-073015

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026